Last reviewed · How we verify
CKD-378, QD, PO
At a glance
| Generic name | CKD-378, QD, PO |
|---|---|
| Sponsor | Chong Kun Dang Pharmaceutical |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Clinical Study to Evaluate the Food Effect of CKD-378 in Healthy Volunteers (PHASE1)
- A Clinical Trial to Evaluate the Food Effect of CKD-378 (PHASE1)
- A Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics of CKD-378 (PHASE1)
- Clinical Trial to Investigate the Pharmacokinetics and Safety After Oral Administration of CKD-378 and Co-administration of D745, D150, D029 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CKD-378, QD, PO CI brief — competitive landscape report
- CKD-378, QD, PO updates RSS · CI watch RSS
- Chong Kun Dang Pharmaceutical portfolio CI